A clinical trial of ZVS101e for treatment of crystallization-like retinitis pigmentosa caused by CYP4V2 biallelic mutations
Latest Information Update: 10 May 2023
At a glance
- Drugs ZVS 101e (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- 10 May 2023 New trial record